ABSTRACT The ease with which emerging SARS-CoV-2 variants escape neutralizing antibodies limits the protection afforded by a prior exposure , be it infection or vaccination. While rare, broadly neutralizing antibodies with activity toward diverse sarbecoviruses have been detected in convalescent serum . Motivated by findings that plasma responses show increased neutralization breadth and potency with continued antigen exposure , we isolated monoclonal antibodies (mAbs) after a SARS-CoV-2 re-infection and compared them to those isolated 1 year prior, after the first breakthrough infection. Among clonal lineage members identified at both time points, mAbs from the later time point showed improved neutralization potency and breadth . One mAb isolated after re-infection, C68.490, targets a conserved region in the receptor binding domain and shows remarkable activity not only against SARS-CoV-2 variants, but also diverse sarbecoviruses from more distant clades present in animal reserv...
Highlights • Transmission of mpox continues in sexual networks , affecting both women and men , and in some historically endemic areas . - All clades of monkeypox virus (MPXV) continue to circulate. - Unless mpox outbreaks are rapidly contained and human-to-human transmission is interrupted , there is a risk of sustained community transmission . • In January 2026, 50 countries across all WHO regions reported a total of 1334 new confirmed mpox cases , including three deaths (case fatality ratio [CFR] 0.2%). - Of these cases , 66% were reported in the African Region. • Four regions observed a decline in confirmed cases in January, compared to December 2025, while the European Region reported an increase in confirmed cases. • Twenty countries in Africa reported active transmission of mpox in the last six weeks (5 January – 15 February 2026), with 1142 confirmed cases, including four deaths (CFR 0.4%). - Countries reporting the highes...